Lymphoid Malignancies
Pipeline by Development Stage
Drug Modality Breakdown
On Market (2)
Approved therapies currently available
Competitive Landscape
6 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Clinical Trials (6)
Total enrollment: 213 patients across 6 trials
Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS
A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies
A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.